Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company has exclusively inlicensed a VR1 project, which is in clinical phase and targeting neuropathic pain, from the Swedish company Acturum Life AB.The VR1 project is in the clinical development phase, and AlzeCure's aim is to develop a new topical local treatment for neuropathic pain. The mechanism of action of the project is via VR1 receptors,

Valmet and Fabio Perini start Industrial Internet ecosystem partnership to provide digital solutions for tissue production and converting

Valmet Oyj's trade press release on January 7, 2020 at 11.00 a.m. EET Valmet and Fabio Perini have established an Industrial Internet ecosystem partnership to strengthen collaboration in the tissue industry. The target is to allow tissue producers and converters to work together more efficiently, and to exchange knowledge and resources for the benefit of their customers. The partnership combines Valmet's comprehensive tissue making technology and process optimization know-how with Fabio Perini’s strong expertise in complete solutions for converting and packaging machines as well as in

Scandinavian ChemoTech strengthens its working capital

ChemoTech has today signed loan agreements that secures finance of four million SEK from shareholders and investors.Through this financing, ChemoTech has increased liquidity, which ensures that the company can complete the CE-marking process for IQwave™, the company's first product based on the patented tumour-specific electroporation technology, and can continue to work on our prioritized markets. The board will continue to establish the long-term financing plan for the company. “We are pleased to see that the long-term interest and trust in ChemoTech, and its potential, from

2020 Bulkers Ltd. (2020) – Company Presentation

2020 Bulkers Ltd. will be presenting at SEB Nordic Seminar in Copenhagen on January 7, 2020. Please see the attachment for the full presentation. For further queries, please contact:  Magnus Halvorsen, Chief Executive Officer,  Telephone +47 920 20 111   About 2020 Bulkers Limited 2020 Bulkers has five vessels in operation and three Newcastlemax dry bulk vessels under construction at New Times Shipyard in China. All vessels will be fitted with exhaust scrubber systems. All ships are expected to be delivered by May 2020.

EQT invests in Asia based Health Management International

· EQT Mid Market Asia invests in Health Management International, a reputable private healthcare provider with regional presence in Singapore, Malaysia and Indonesia · EQT will support Health Management International in realizing its full potential while scaling the Company’s platform in the region, organically and by exploring potential future acquisition opportunities · Health Management International was delisted from the Singapore Exchange on 24 December 2019 The EQT Mid Market Asia III fund (“EQT Mid Market Asia” or “EQT”) today announced its investment in Health

Wärtsilä Exhaust Gas Cleaning system gets CCS Type Approval

Wärtsilä Corporation, Trade press release, 7 January 2020 at 10 am EETThe technology group Wärtsilä’s Exhaust Gas Cleaning (EGC ) system has been Type Approved in China by the China Classification Society (CCS). This follows the order for the system from Dalian Shipbuilding Industry for installation onboard the ‘New Treasure’, a new Very Large Crude Carrier (VLCC). The ship is being built for Associated Maritime of Hong Kong, part of the China Merchants Energy Shipping group, the largest VLCC owner in China and a world leading crude

FluoGuide strengthen its protection on FG001 with the European granting of patent

FluoGuide A/S (“FluoGuide”) is pleased to announce the grant of European patent No. EP3193945 “uPAR targeting peptide for use in peroperative optical imaging of invasive cancer”, which is the core patent protecting FG001 in Europe. The patent protection is valid until September 2034. The FG001 product patent was granted in USA (US10,111,969B2) in 2018.FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of their cure. It can also reduce costs for the health

ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a specific divisional U.S. patent was issued in 2018.AdaptVac’s novel capsid virus-like particle (VLP) technology platform shows strong potential as a platform for the development of novel breakthrough

Senzime receives new mayor order from South Korea and passes 400 delivered TetraGraph

Press release: Uppsala, January 7, 2020. Senzime AB (publ) today announces that they have received a new order of TetraGraph systems and single use electrodes from their distributor in South Korea. The order value amounts to approximately 1,5 MSEK and delivery will take place during the current month.This is the third large order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used. Senzime’s

Bublar Group receives order for approx. SEK 2 million

Bublar’s subsidiary Vobling will deliver a software solution as part of a digital application. The order value amounts to approximately SEK 2 million. The aim is to create a completely new form of visualization and interactive planning to become your own interior designer for the next generation shopping experience. In this project, Vobling will cooperate with Goodbye Kansas and deliver the application’s XR-solution. This is yet another collaboration with Goodbye Kansas where Vobling already are working together within our framework agreement with Scania. Goodbye Kansas is the

Smart Eye receives design win from second Chinese OEM

Smart Eye AB (Nasdaq: SEYE), the market leader in Driver Monitoring Systems, receives one new design wins, from a second Chinese OEM customer. The estimated revenue of the order is MSEK 50, based on forecasts of the estimated product life cycle, the company has now received a total of 57 design wins.Smart Eye will deliver its second-generation DMS technology to a large Chinese OEM. The car models that includes Smart Eye’s software have a planned SOP in 2021. Smart Eye’s DMS software includes an in-car AI function to increase the safety and entertainment of the driver. The system includes

TFB Holding’s ownership in TF Bank

TF Bank’s largest owner TFB Holding AB has informed the company that part of the holding in TF Bank has been transferred to Tiberon AB.Through the transfer, one of TFB Holding’s owners will hold the shares in TF Bank directly via Tiberon AB. Following the transfer Tiberon AB holds 3,179,291 shares in TF Bank, corresponding to approx. 14.8 percent of capital and votes. The transaction has been published in the Swedish Financial Supervisory Authority’s PDMR transactions register. For further information, please contact:Mikael Meomuttel, CFO and Head of Investor Relations +46 (0)70 626 95

Results from Realheart's latest trial series: The sheep was awakened and able to eat

Realheart has successfully completed this fall's animal trail series. During the last operation in December, the sheep survived the entire critical post-operation phase with stable vital signs. The animal could be awakened and then eat by itself. The result of the operation means that the company has already reached the trial series goals. Therefore, it has been decided to refrain from the fifth and final operation planned for January.In the spring of 2019, a series of successful surgeries were performed in which Realheart achieved crucial milestones in terms of improving implant technology.

Herantis Pharma publishes newsletter for November-December

Herantis Pharma PlcPress release 7 January 2020 at 9:00 am EETHerantis Pharma plc (“Herantis”) has published its newsletter for November-December 2019. The newsletter is also attached to this press release. Herantis’ newsletter is published every other month on the company’s web site . It is also available by email subscription . Further information: Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445Company web site: www.herantis.com About Herantis Pharma Plc Herantis Pharma

Insplorion sells an XNano instrument to Dr. Tim Craggs at the University of Sheffield, UK

Dr. Tim Craggs’ research at Department of Chemistry at the University of Sheffield is an interdisciplinary lab working within life science to, among others, address questions of protein folding, and DNA transcription, replication and repair. This is the first sales of Insplorion Instruments to UK.The contact with the Sheffield group was initiated in 2016 by Insplorion’s distributor ATG Scientific which resulted in a successful pre-study. Research funding in UK has suffered from all unknowns related to Brexit, delaying all finance related activities. The sales and the main parts of the

Finnair Traffic Performance in December 2019

Finnair Plc          Investor News        7 January 2020 at 9:00 am   Passenger load factor improved in December year-on-year and annual number of passengers reached new all-time high with 14.7 million and 10.3% growth   In December, Finnair experienced strong demand and carried 1,154,000 passengers, 11.7% more than in the corresponding period of 2018. The overall capacity measured in Available Seat Kilometres (ASK) increased in December by 12.3%. Finnair's traffic measured in Revenue Passenger Kilometres (RPKs) increased by 13.5%, and the Passenger Load Factor (PLF) increased year-on-

Artificial Solutions and Vonage Partner to Deliver Closer Integration

Stockholm, Sweden (7 January 2020) – Artificial Solutions ® (SSME:ASAI ) the leading specialist in enterprise-strength Conversational AI, announced today that it has signed a partnership agreement with Vonage and introduced a new connector that integrates Teneo® into Vonage’s API Platform. Teneo customers can now deploy their conversational AI applications into new channels by leveraging the Vonage API Platform (CPaaS - Communications Platforms as a Service) technology, which makes it easier to manage

Heimstadenen strengthens its management team

Magnus Nordholm returns to Heimstaden to lead the collaboration with institutional investorsMagnus Nordholm has been CEO of Fredensborg AS since January 2019, but as a result of Heimstaden's international expansion he will spend all his time in Heimstaden going forward. "Magnus will as of today become deputy CEO of Heimstaden AB with responsibility for Equity, Partners and M&A and I return to the role as CEO of Fredensborg AS. Today, Norway is a small part of our business. Our growth is taking place in other European countries and the most important thing Magnus can do going forward is

IRRAS Provides US Launch Update, Product Portfolio Progress and Objectives for 2020

Stockholm, January 7, 2020 – IRRAS, a global healthcare company with a comprehensive portfolio of innovative solutions for neurocritical care, today provides an update on the launch of its products in the United States (US) and product portfolio objectives for 2020.  "We are excited to report on the growth and expansion of IRRAS’ IRRAflow® and Hummingbird ICP monitoring product lines," said Kleanthis G. Xanthopoulos, Ph.D., President & CEO of IRRAS. "The CE Mark recertification of IRRAflow and the US launches of IRRAflow and Hummingbird provide IRRAS with good opportunities to meet our

Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs

STOCKHOLM — January 7, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides. Karin has 20 years of experience from senior positions in regulatory affairs. Prior to joining Oncopeptides, she served as Global Regulatory Director at Swedish Orphan Biovitrum. She will be a member Oncopeptides’ Management Team and will start today. Elisabeth Augustsson, who has been responsible for Oncopeptides’ regulatory function since 2015 will continue in a senior role in the regulatory team.For more

Borr Drilling Limited appoints Francis Millet as new Chief Financial Officer

Borr Drilling Limited (NYSE: BORR, OSE: BDRILL) (the “Company” or “Borr”) announces that Mr. Francis Millet has been appointed as the new Chief Financial Officer of the Company.  Mr. Millet has 30 years of experience at Schlumberger where he has held several senior management functions globally, including VP Commercial and Finance and VP Commercial and Contracts. He brings with him vast knowledge and experience in finance, business development, M&A, risk management, accounting and tax.  Mr. Millet is a chartered accountant and holds a Master in business administration from Paris

poLight ASA – Smartwatch launched with advanced autofocus functionality based on poLight TLens

Horten, 7th January 2020 - poLight ASA (OSE: PLT) today announced that its TLens product is being used in a smartwatch for children launched to market on 7th January 2020. The OEM is undisclosed. The watch has two cameras, one main camera used to take pictures which includes an advanced autofocus (AF) function delivered by poLight, and one camera integrated in the screen used for face camera without AF. “This is an important milestone for poLight and we are very proud to be included in this innovative smartwatch flagship”, said Dr. Øyvind Isaksen, the CEO of poLight.

Share buy-backs in Telia Company during week 1 2020

During the period December 30, 2019 until January 3, 2020, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 1,702,796 own shares (ISIN: SE0000667925).The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

Bittium joins Rightware’s Kanzi Partner Program and showcases OEM application management and secure solutions on Android™ Automotive platform at CES 2020

Press Release Free for release on January 7, 2020 at 8.30 am (CET +1) Bittium joins Rightware’s Kanzi Partner Program and showcases OEM application management and secure solutions on Android™ Automotive platform at CES 2020 Oulu, Finland, January 7, 2020 – Bittium joins Rightware’s Kanzi partner program and demonstrates together with Rightware the integration of Bittium SafeMove® application management solution and cloud service with Rightware’s Kanzi reference HMI (Human Machine Interface) platform at CES 2020 in Las Vegas 7-10 January 2020. The demo will feature Android™

There are no items matching the current filter
There are no more items matching the current filter
Back to top